Comprehensive Insight Into Atopic Dermatitis: Understanding Disease Burden, Treatment Strategies and Emerging Therapies : Episode 6

Recent Advancements in AD Treatment

April 2, 2025

By Matthew Zirwas, M.D.

Opinion

Video

An expert discusses the advancements in systemic and targeted therapies that have had the most significant impact on atopic dermatitis (AD) treatment in recent years as well as the cost-effectiveness and real-world outcomes of biologics and Janus kinase (JAK) inhibitors compared with traditional systemic therapies for AD

EP: 1.Clinical Presentations of Atopic Dermatitis Across Patient Populations

EP: 2.Hidden Burden of AD

EP: 3.Topical Treatments in AD

EP: 4.Shared Decision-Making in AD Management

EP: 5.Overcoming Barriers to Treatment in AD

Now Viewing

EP: 6.Recent Advancements in AD Treatment

EP: 7.Integrating New AD Therapies Into Clinical Practice

EP: 8.Key Takeaways for AD Management

Video content above is prompted by the following:

In your opinion, what advancements in systemic and targeted therapies have had the most significant impact on AD treatment in recent years?
Based on your experience, how do the cost-effectiveness and real-world outcomes of biologics and JAK inhibitors compare with traditional systemic therapies for AD in your patient population?

Related Content

Value-Based Decision-Making in Metastatic Breast Cancer

Ian E. Krop, MD, PhD;Debra Patt, MD, PhD, MBA

September 16th 2021

Article

In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.